Cancer remains one of the leading causes of death in the United States, but decades of progress in prevention, early detection, and treatment are making a difference. The latest national cancer report, released in September 2026, confirms that cancer death rates continue to decline, even as the rate of new diagnoses has increased for some cancers.
According to the 2026 Annual Report to the Nation on the Status of Cancer, overall cancer death rates fell between 2019 and 2023, while cancer incidence increased slightly between 2018 and 2022, driven in part by rising rates of breast and prostate cancer. The findings highlight an important distinction: more people may be diagnosed with cancer even as fewer people die from it.
These trends represent meaningful progress, but they also reveal an ongoing challenge. The benefits of cancer prevention, screening, and treatment are not reaching every population equally.
Understanding why cancer deaths are falling—and where progress remains uneven—can help patients, healthcare providers, employers, and policymakers identify opportunities to improve outcomes.
Why Are Cancer Death Rates Declining?
The decline in cancer mortality reflects several decades of progress rather than a single medical breakthrough. Reduced tobacco use, advances in treatment, and improvements in early detection have all contributed.
The American Association for Cancer Research reported in its 2026 Cancer Progress Report that the overall U.S. cancer death rate declined by 35% between 1991 and 2024. The decline represents more than 4.8 million cancer deaths averted compared with what would have occurred if mortality had remained at its historical peak.
These estimates illustrate the impact of sustained public health efforts and medical innovation.
Fewer smoking-related deaths
Reducing tobacco use has been one of the most important contributors to lower cancer mortality. Cigarette smoking is associated with lung cancer and numerous other cancers, and it remains a major preventable cause of cancer deaths.
As smoking rates have declined, deaths from lung cancer and several other smoking-related cancers have also fallen.
However, the benefits of tobacco prevention do not eliminate the need for continued efforts. Smoking cessation, prevention programs, and access to evidence-based treatment remain essential, particularly for people who currently smoke or have a long history of tobacco exposure.
Better screening and earlier detection
Cancer screening can identify certain cancers before symptoms develop. Some screening tests can also detect precancerous changes that can be treated before cancer develops.
For example, colorectal cancer screening can identify precancerous polyps, while breast and cervical cancer screening can help detect disease at earlier stages.
The benefits depend on selecting appropriate tests for the right populations and ensuring that patients receive timely follow-up.
The Centers for Disease Control and Prevention’s cancer screening guidance explains which screening approaches are recommended for different cancer types and highlights the importance of appropriate screening.
For additional consumer guidance, see GoodMorningHealthcare.com’s articles on which cancer screening tests make sense and at-home colon cancer tests.
Advances in cancer treatment
Cancer treatment has evolved significantly, giving clinicians more options for managing many types of disease.
Surgery, radiation therapy, chemotherapy, and hormone therapy remain important components of cancer care. They are increasingly complemented by targeted therapies, immunotherapies, and molecular testing that can help clinicians select treatments based on the characteristics of an individual tumor.
These advances have improved outcomes for some cancers, including certain types that were historically difficult to treat.
Nevertheless, treatment effectiveness varies considerably by cancer type, stage, and tumor biology. New therapies may offer substantial benefits to some patients while providing limited benefit to others.
The continued decline in cancer mortality reflects the combined effects of prevention, earlier detection, and improved treatment—not a single universal cure.
Cancer Mortality Is Not Declining Equally for Everyone
National statistics can obscure substantial differences in cancer outcomes across populations.
Cancer mortality varies by cancer type, race and ethnicity, geography, socioeconomic circumstances, and access to healthcare. Differences in exposure to risk factors, preventive services, diagnostic delays, and treatment access can all contribute.
The National Cancer Institute provides detailed information through its cancer statistics resources, which help researchers and healthcare organizations evaluate differences in cancer incidence, mortality, and survival.
Access to care remains a major challenge
Patients in rural communities may need to travel long distances to reach screening facilities, cancer specialists, radiation therapy centers, or clinical trials.
For others, the obstacles may involve insurance coverage, high out-of-pocket costs, limited paid leave, transportation, or difficulty coordinating appointments among multiple specialists.
These barriers can delay diagnosis or interrupt treatment.
Insurance coverage is important, but having an insurance card does not guarantee timely access to appropriate care. Deductibles, provider networks, authorization requirements, and medication costs can influence whether patients obtain recommended services.
For healthcare organizations and payers, reducing cancer mortality requires looking beyond whether a service is covered. It also requires evaluating whether patients can access and complete the care they need.
Prevention and screening gaps can widen disparities
Cervical cancer illustrates why access to preventive services matters. Human papillomavirus (HPV) vaccination can prevent infections associated with most cervical cancers, while recommended screening can identify precancerous changes or disease at an earlier stage.
Similarly, colorectal cancer screening offers opportunities to detect cancer earlier and, in some cases, prevent it by identifying precancerous polyps.
However, the benefits of these interventions depend on access to vaccination, screening, diagnostic follow-up, and treatment.
An abnormal screening result is not the end of the process. Patients need timely diagnostic evaluation and appropriate care. When follow-up is delayed or does not occur, some of the potential benefit of screening can be lost.
Reducing disparities therefore requires more than making screening tests available. It requires systems that help patients move from screening to diagnosis and, when necessary, treatment.
Earlier Cancer Detection Helps—but Screening Has Limits
Early detection is an important component of cancer control, but screening is not appropriate for every cancer or every person.
A screening test is intended to identify disease in people who do not have symptoms. Its benefits and risks depend on the cancer being screened for, the person’s age and risk factors, the test’s accuracy, and what happens after a result is obtained.
Screening can produce false-positive results that lead to additional testing, anxiety, or invasive procedures. It can also identify some cancers that would not have caused symptoms or affected a person’s lifespan. This is known as overdiagnosis.
For these reasons, screening decisions should reflect evidence-based recommendations and individual circumstances.
Lung cancer screening is one example
Lung cancer remains a major cause of cancer deaths in the United States. Annual screening with low-dose computed tomography (LDCT) can reduce lung cancer mortality among eligible people at high risk.
The U.S. Preventive Services Task Force recommends annual LDCT screening for adults ages 50 to 80 who have at least a 20 pack-year smoking history and currently smoke or quit within the past 15 years.
A pack-year represents smoking one pack of cigarettes daily for one year; the calculation also accounts for people who smoked different amounts over longer or shorter periods.
The recommendation applies to people who meet the specified risk criteria, not to everyone. Screening decisions should also consider overall health, the ability to undergo further diagnostic evaluation, and the potential benefits and harms.
The U.S. Preventive Services Task Force’s lung cancer screening recommendation provides details about eligibility and the evidence supporting screening.
Symptoms still deserve medical attention
Routine screening does not replace evaluation of concerning symptoms.
Persistent changes in bowel or bladder habits, unexplained bleeding, a new lump, difficulty swallowing, unexplained weight loss, or a cough that does not improve may have many possible causes. However, persistent or unusual symptoms should be discussed with a qualified healthcare professional.
People should not wait for their next routine screening appointment if they develop symptoms that warrant evaluation.
Cancer Prevention Remains Essential
Although advances in cancer treatment often receive the most attention, prevention remains one of the most powerful ways to reduce the long-term burden of disease.
Evidence-based prevention strategies include avoiding tobacco, limiting alcohol consumption, maintaining a healthy weight when possible, staying physically active, protecting skin from excessive ultraviolet exposure, and receiving recommended vaccinations.
Some of these measures can reduce the risk of developing particular cancers. Others contribute to overall health and may influence cancer risk indirectly.
However, prevention is not entirely within an individual’s control. Age, inherited genetic factors, workplace exposures, environmental conditions, and other influences can contribute to cancer risk.
A cancer diagnosis should never be treated as evidence that someone failed to make the right lifestyle choices.
The goal is to make effective preventive measures more accessible while supporting research into the biological and environmental factors that contribute to disease.
For more information about the relationship between alcohol and cancer, readers can explore GoodMorningHealthcare.com’s article on alcohol consumption and cancer risk.
Healthcare systems can make prevention easier
Healthcare organizations can improve participation in preventive services through practical interventions, including:
- Reminders for patients who are due for recommended screening.
- Multilingual educational materials tailored to different communities.
- Mobile screening programs and partnerships with community organizations.
- Patient navigation to help people complete diagnostic testing and treatment.
- Outreach to people who have missed appointments or face access barriers.
- Follow-up systems that track abnormal screening results until the next appropriate step is completed.
Digital tools can support these efforts by helping healthcare teams identify patients who may be overdue for screening or need additional assistance.
But technology alone is not enough. Effective prevention programs require reliable follow-up, accessible services, and communication that patients understand and trust.
What Cancer Statistics Mean for Patients and Families
Population-level statistics are valuable for understanding trends, but they cannot predict an individual’s outcome.
A person’s prognosis depends on several factors, including the cancer type, stage at diagnosis, tumor biology, overall health, available treatment options, and response to therapy.
Survival statistics also require careful interpretation. They are based on groups of patients, and the data may reflect treatments that were available years earlier. They cannot account fully for the benefits of every recent medical advance.
For people concerned about cancer, several practical steps can help.
First, ask about recommended screening. A healthcare professional can help determine which tests are appropriate based on age, medical history, family history, and individual risk.
Second, follow up on abnormal results. An abnormal screening result does not necessarily mean cancer is present, but it may require additional testing.
Third, discuss persistent symptoms. Do not assume that a concerning symptom can wait until the next routine appointment.
Fourth, understand the diagnosis. For patients with cancer, questions about the stage, pathology findings, treatment goals, potential side effects, and available options can help guide discussions with the care team.
Finally, raise practical concerns early. Transportation, treatment costs, work schedules, and caregiving responsibilities can affect a patient’s ability to complete treatment. Healthcare teams may be able to connect patients with financial counselors, social workers, transportation assistance, or other support services.
Family members and caregivers can also help by tracking appointments, medications, symptoms, and questions for clinicians.
These forms of support can be especially important when treatment involves multiple specialists and a series of complex decisions.
Measuring Cancer Progress Beyond the Death Rate
A declining cancer mortality rate is an encouraging sign, but it is not the only measure of progress.
Healthcare leaders should also examine cancer incidence, stage at diagnosis, time from an abnormal screening result to diagnostic evaluation, treatment completion, patient experience, financial hardship, and differences in outcomes across communities.
These measures help explain why mortality is changing and where healthcare systems may need to intervene.
For example, an effective screening program may have limited impact if patients cannot obtain follow-up testing. A new treatment may improve outcomes in clinical trials but have a smaller effect across the population if eligible patients cannot access it.
Healthcare organizations should therefore evaluate the entire care pathway—from prevention and screening through diagnosis, treatment, and survivorship.
This approach can help identify practical opportunities to improve outcomes, including reducing delays, coordinating care, addressing affordability, and expanding access to evidence-based services.
The Bottom Line: Cancer Progress Must Reach More People
The decline in U.S. cancer death rates demonstrates the value of sustained prevention efforts, scientific research, earlier detection, and improved treatment.
Yet the increasing number of diagnoses for some cancers and persistent differences in outcomes show why the work is far from complete.
The next phase of progress will require continued investment in research, effective prevention programs, accessible screening, a strong oncology workforce, and healthcare systems that help patients receive appropriate care without avoidable delays.
It will also require measuring success in ways that reveal whether advances are benefiting different communities—not just whether the national average is improving.
The ultimate goal is not simply to lower the cancer death rate. It is to ensure that more people have a realistic opportunity to prevent cancer, receive an early diagnosis when possible, access effective treatment, and live longer, healthier lives.
Medical information disclaimer: This article is intended for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Screening recommendations depend on individual risk factors and may change as new evidence becomes available. Consult a qualified healthcare professional about personal screening and treatment decisions.
Thank you, You will be automatically subscribed to the our newsletter.